X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (141) 141
index medicus (136) 136
multiple myeloma (132) 132
hematology (100) 100
monoclonal gammopathy (94) 94
oncology (92) 92
female (62) 62
male (61) 61
disease progression (59) 59
middle aged (58) 58
aged (57) 57
prognosis (54) 54
multiple myeloma - diagnosis (51) 51
smoldering multiple myeloma (50) 50
smoldering multiple-myeloma (50) 50
progression (46) 46
risk factors (44) 44
adult (43) 43
smoldering myeloma (43) 43
smoldering (42) 42
undetermined significance (41) 41
diagnosis (37) 37
risk (36) 36
aged, 80 and over (35) 35
multiple myeloma - pathology (33) 33
undetermined significance mgus (32) 32
monoclonal gammopathy of undetermined significance (31) 31
article (28) 28
monoclonal gammopathy of undetermined significance - diagnosis (28) 28
bone marrow (27) 27
care and treatment (26) 26
hemic and lymphatic diseases (25) 25
therapy (25) 25
long-term (24) 24
cancer (23) 23
patients (23) 23
mgus (22) 22
multiple myeloma - therapy (22) 22
myeloma (22) 22
thalidomide (22) 22
development and progression (21) 21
multiple myeloma - drug therapy (21) 21
criteria (20) 20
hematology, oncology and palliative medicine (20) 20
plasma cells (19) 19
stem-cell transplantation (19) 19
survival (19) 19
bone marrow - pathology (18) 18
malignant-transformation (17) 17
multiple myeloma - genetics (17) 17
monoclonal gammopathy of undetermined significance - pathology (16) 16
multiparameter flow-cytometry (16) 16
research (16) 16
flow cytometry (15) 15
medicine, general & internal (15) 15
zoledronic acid (15) 15
immunoglobulins (14) 14
lenalidomide (14) 14
light-chain ratio (14) 14
multiple-myeloma (14) 14
plasma cells - pathology (14) 14
plasma-cells (14) 14
treatment (14) 14
follow-up studies (13) 13
genetic aspects (13) 13
medicine & public health (13) 13
multiple myeloma - etiology (13) 13
prevalence (13) 13
prognostic-significance (13) 13
survival rate (13) 13
amyloidosis (12) 12
disease (12) 12
follow-up (12) 12
gammopathy (12) 12
magnetic resonance imaging (12) 12
management (12) 12
multiple myeloma - metabolism (12) 12
multiple myeloma - mortality (12) 12
treatment outcome (12) 12
biomarkers (11) 11
diagnosis, differential (11) 11
expression (11) 11
health aspects (11) 11
lenalidomide plus dexamethasone (11) 11
marrow plasma-cells (11) 11
monoclonal gammopathy of undetermined significance - complications (11) 11
monoclonal gammopathy of undetermined significance - epidemiology (11) 11
pathology (11) 11
proteins (11) 11
significance mgus (11) 11
stage-i (11) 11
antineoplastic agents - therapeutic use (10) 10
bone-marrow (10) 10
lymphomas (10) 10
medical research (10) 10
monoclonal gammopathies (10) 10
monoclonal gammopathy of undetermined significance - genetics (10) 10
monoclonal gammopathy of undetermined significance - therapy (10) 10
multiple myeloma - blood (10) 10
multiple myeloma - epidemiology (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 676 - 681
Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias, which... 
Health disparity | MGUS | Smoldering myeloma | Epidemiology | Multiple myeloma | CRITERIA | POPULATION | PROGNOSIS | LONG-TERM SURVIVAL | NATIONAL-HEALTH | RACIAL DISPARITIES | YOUNGER | ONCOLOGY | MONOCLONAL GAMMOPATHY | UNDETERMINED SIGNIFICANCE MGUS | Multiple Myeloma - epidemiology | Multiple Myeloma - therapy | Time Factors | Multiple Myeloma - mortality | Humans | Middle Aged | Aged, 80 and over | Adult | Aged
Journal Article
Journal Article
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 666 - 675
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 695 - 696
Multiple myeloma (MM) is a hematologic malignancy of the plasma cell that causes symptoms of bone pain, renal failure, and anemia. It is usually preceded by a... 
Smoldering multiple myeloma | Multiple myeloma | Plasma cell | CRITERIA | ONCOLOGY | MONOCLONAL GAMMOPATHY | PROGRESSION | ASYMPTOMATIC MULTIPLE-MYELOMA | Male | Multiple Myeloma - therapy | Humans | Middle Aged
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 690 - 694
Journal Article
Seminars in Oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 697 - 699
In a 2008 paper, Dispenzieri and colleagues at the Mayo Clinic proposed a risk stratification system for patients with smoldering multiple myeloma (SMM) based... 
Smoldering multiple myeloma | Treatment | Risk stratification | DEXAMETHASONE | EXTENSION | TRIAL | IMPACT | THERAPY | ONCOLOGY | MONOCLONAL GAMMOPATHY | STEM-CELL TRANSPLANTATION | PROGRESSION | ASYMPTOMATIC MULTIPLE-MYELOMA | Multiple Myeloma - etiology | Multiple Myeloma - therapy | Humans | Middle Aged | Risk Factors | Male | Disease Progression
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2007, Volume 136, Issue 3, pp. 393 - 399